Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2004 1
2005 1
2006 2
2007 1
2008 2
2009 3
2010 3
2011 1
2013 1
2014 3
2019 1
2020 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Human choriogonadotropin and epoetin alfa in acute ischemic stroke patients (REGENESIS-LED trial).
Cramer SC, Hill MD; REGENESIS-LED Investigators. Cramer SC, et al. Int J Stroke. 2014 Apr;9(3):321-7. doi: 10.1111/ijs.12260. Epub 2014 Mar 3. Int J Stroke. 2014. PMID: 24588854 Clinical Trial.
INTRODUCTION: Preclinical studies suggest that growth factors in the early days after stroke improve final outcome. A prior study found three doses of human choriogonadotropin alfa followed by three doses of erythropoietin to be safe after stroke in humans. ...Patie …
INTRODUCTION: Preclinical studies suggest that growth factors in the early days after stroke improve final outcome. A prior study found thre …
Outcomes of new quality standards of follitropin alfa on ovarian stimulation: meta-analysis of previous studies.
Saz-Parkinson Z, López-Cuadrado T, Bouza C, Amate JM. Saz-Parkinson Z, et al. BioDrugs. 2009;23(1):37-42. doi: 10.2165/00063030-200923010-00004. BioDrugs. 2009. PMID: 19344190 Review.
Several clinical trials have tried to assess the clinical implications of the physicochemical improvements in the dosing of follitropin alfa filled by mass (FbM). The aim of this study was to perform a meta-analysis of previous studies in order to assess the efficacy and s …
Several clinical trials have tried to assess the clinical implications of the physicochemical improvements in the dosing of follitropin a …
Dose-dependent stimulation of human follicular steroidogenesis by a novel rhCG during ovarian stimulation with fixed rFSH dosing.
Bøtkjær JA, Kristensen SG, Olesen HØ, Larsson P, Mannaerts B, Andersen CY. Bøtkjær JA, et al. Front Endocrinol (Lausanne). 2022 Oct 20;13:1004596. doi: 10.3389/fendo.2022.1004596. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36339420 Free PMC article. Clinical Trial.
BACKGROUND: Choriogonadotropin (CG) beta (FE 999302), a novel recombinant human (h)CG produced by a human cell line, has a longer half-life and higher potency than CG alfa produced by a Chinese hamster ovary cell line. hCG augments steroid production, but the extent …
BACKGROUND: Choriogonadotropin (CG) beta (FE 999302), a novel recombinant human (h)CG produced by a human cell line, has a longer hal …
Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF.
Fauser BC, Alper MM, Ledger W, Schoolcraft WB, Zandvliet A, Mannaerts BM; Engage Investigators. Fauser BC, et al. Reprod Biomed Online. 2010 Nov;21(5):593-601. doi: 10.1016/j.rbmo.2010.06.032. Epub 2010 Jun 30. Reprod Biomed Online. 2010. PMID: 20843746 Clinical Trial.
By stimulation day 8, 33% of patients treated with corifollitropin alfa reached the criterion for human chorionic gonadotrophin (HCG) injection. ...Serum FSH immunoreactivity levels were higher up to stimulation day 5 for corifollitropin alfa compared with th …
By stimulation day 8, 33% of patients treated with corifollitropin alfa reached the criterion for human chorionic gonadotrophi …
Recombinant human luteinizing hormone, lutropin alfa, for the induction of follicular development and pregnancy in profoundly gonadotrophin-deficient women.
Kaufmann R, Dunn R, Vaughn T, Hughes G, O'Brien F, Hemsey G, Thomson B, O'Dea LS. Kaufmann R, et al. Clin Endocrinol (Oxf). 2007 Oct;67(4):563-9. doi: 10.1111/j.1365-2265.2007.02925.x. Epub 2007 Aug 13. Clin Endocrinol (Oxf). 2007. PMID: 17692110 Clinical Trial.
OBJECTIVE: To provide evidence of efficacy and safety for use of lutropin alfa in inducing follicular development and pregnancy in hypogonadotrophic hypogonadal women with profound gonadotrophin deficiency. ...One patient was hospitalized for severe ovarian hyperstimulatio …
OBJECTIVE: To provide evidence of efficacy and safety for use of lutropin alfa in inducing follicular development and pregnancy in hy …
Short follicular phase of stimulation following corifollitropin alfa or daily recombinant FSH treatment does not compromise clinical outcome: a retrospective analysis of the Engage trial.
Mardešič T, Mannaerts B, Abuzeid M, Levy M, Witjes H, Fauser BC; Engage investigators. Mardešič T, et al. Reprod Biomed Online. 2014 Apr;28(4):462-8. doi: 10.1016/j.rbmo.2013.12.009. Epub 2014 Jan 24. Reprod Biomed Online. 2014. PMID: 24581989 Clinical Trial.
In the corifollitropin alfa and recombinant FSH groups, 23.2% and 29.1%, respectively, were early responders (P=0.01). ...The number of oocytes was similar in both response groups following corifollitropin alfa treatment (13.6 versus 14.5) and recombinant FSH treatm …
In the corifollitropin alfa and recombinant FSH groups, 23.2% and 29.1%, respectively, were early responders (P=0.01). ...The number …
Corifollitropin alfa or rFSH treatment flexibility options for controlled ovarian stimulation: a post hoc analysis of the Engage trial.
Leader A, Devroey P, Witjes H, Gordon K. Leader A, et al. Reprod Biol Endocrinol. 2013 Jun 11;11:52. doi: 10.1186/1477-7827-11-52. Reprod Biol Endocrinol. 2013. PMID: 23758821 Free PMC article. Clinical Trial.
Efficacy outcomes were assessed on patients from the Engage trial who started treatment on menstrual cycle day 2 versus menstrual cycle day 3, patients who received rFSH step-down or fixed-dose rFSH, patients who received rFSH on the day of human chorionic gonadotropin …
Efficacy outcomes were assessed on patients from the Engage trial who started treatment on menstrual cycle day 2 versus menstrual cycle day …
Safety and efficacy of mixing cetrorelix with follitropin alfa: a randomized study.
Lin YH, Wen YR, Chang Y, Seow KM, Hsieh BC, Hwang JL, Tzeng CR. Lin YH, et al. Fertil Steril. 2010 Jun;94(1):179-83. doi: 10.1016/j.fertnstert.2009.02.062. Epub 2009 Apr 1. Fertil Steril. 2010. PMID: 19339001 Free article. Clinical Trial.
OBJECTIVE: To assess the safety and efficacy of mixing cetrorelix with follitropin alfa (rFSH) in assisted reproductive technology. DESIGN: Prospective, randomized study. ...
OBJECTIVE: To assess the safety and efficacy of mixing cetrorelix with follitropin alfa (rFSH) in assisted reproductive technology. D …
A randomized dose-response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation.
Corifollitropin Alfa Dose-finding Study Group. Corifollitropin Alfa Dose-finding Study Group. Hum Reprod. 2008 Nov;23(11):2484-92. doi: 10.1093/humrep/den288. Epub 2008 Aug 6. Hum Reprod. 2008. PMID: 18684735 Clinical Trial.
Patients treated with corifollitropin alfa started fixed daily treatment with 150 IU rFSH on stimulation Day 8. Patients received a GnRH antagonist (ganirelix 0.25 mg/day) from stimulation Day 5 until the day of human chorionic gonadotrophin. RESULTS: Pharmacokineti …
Patients treated with corifollitropin alfa started fixed daily treatment with 150 IU rFSH on stimulation Day 8. Patients received a G …
Replacing HMG/FSH by low-dose HCG to complete corifollitropin alfa stimulation reduces cost per clinical pregnancy: a randomized pragmatic trial.
Decleer W, Comhaire F, Balduyck J, Ameye A, Osmanagaoglu K, Devroey P. Decleer W, et al. Reprod Biomed Online. 2020 Mar;40(3):468-474. doi: 10.1016/j.rbmo.2019.10.008. Epub 2019 Oct 24. Reprod Biomed Online. 2020. PMID: 32057673 Clinical Trial.
This study investigated the effect of using low-dose human chorionic gonadotrophin (HCG) for the second phase of follicular maturation after corifollitropin alfa induction, to replace the more expensive, either recombinant or human menopausal gonadotrophin (HMG), on …
This study investigated the effect of using low-dose human chorionic gonadotrophin (HCG) for the second phase of follicular maturatio …
18 results